Mast-Cell Stabilizing Effects of Olopatadine

This study has been completed.
Sponsor:
Information provided by:
Alcon Research
ClinicalTrials.gov Identifier:
NCT00389025
First received: October 13, 2006
Last updated: January 4, 2010
Last verified: January 2010

October 13, 2006
January 4, 2010
October 2006
April 2007   (final data collection date for primary outcome measure)
Tear histamine
Same as current
Complete list of historical versions of study NCT00389025 on ClinicalTrials.gov Archive Site
Tear cytology, subject evaluation of ocular itching, investigators evaluation of ocular redness
Same as current
Not Provided
Not Provided
 
Mast-Cell Stabilizing Effects of Olopatadine
Mast-Cell Stabilizing Effects of Olopatadine

To assess the effects of olopatadine of the release of mast cell histamine

Not Provided
Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Pharmacodynamics Study
Intervention Model: Single Group Assignment
Masking: Double-Blind
Primary Purpose: Prevention
Allergic Conjunctivitis
Drug: Olopatadine (generic name)
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
24
Not Provided
April 2007   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Asymptomatic and not using any topical or systemic medication

Exclusion Criteria:

  • Age
Both
18 Years and older
Yes
Contact information is only displayed when the study is recruiting subjects
Italy
 
NCT00389025
C-05-30
Not Provided
Not Provided
Alcon Research
Not Provided
Study Director: Terry Wiernas Alcon Research
Alcon Research
January 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP